News Article

Global investment firm EQT is to acquire the biosurgery business unit from Chicago-based private equity firm GTCR’s portfolio company, Corza Medical.

Financial details of the transaction remain undisclosed. The deal, through the EQT X fund, is expected to close in Q4 2026, subject to regulatory clearances and customary closing conditions.

The divestiture represents a significant corporate carve-out for Corza Medical. Under the terms of the agreement, GTCR will retain ownership of Corza Medical’s remaining business units, which include Wound Closure, Ophthalmology, and Biomedical Textiles.

This separation allows Corza Medical to focus resources on its primary surgical technology assets, whilst positioning Corza Biosurgery for a standalone international growth strategy under EQT’s stewardship.

Corza Biosurgery, which employs approximately 400 people globally, is anchored by its Austrian manufacturing facility in Linz and its highly clinical TachoSil patch. The dual-action active biologic patch, a surgical sponge sealant patch used to stop bleeding and seal tissue during operations, is used in cardiovascular, thoracic, neuro, and hepatic surgeries across more than 50 countries.

EQT intends to leverage its extensive healthcare expertise and global network to accelerate TachoSil’s market penetration in the United States, fund geographic and clinical indication expansions, and build a broader biosurgery platform via subsequent complementary acquisitions and partnerships.

To guide this next phase, Thierry Leclercq will continue to lead the business as President, whilst Sheri McCoy, the former Chair of Johnson & Johnson’s Surgical Care Group, is appointed as Board Chair of the standalone company upon closing. EQT X is expected to be approximately 80 to 85 percent invested following the completion of this transaction.